Jeff Norenberg

Founder, CEO and Chairman iSeek Biopharma

Jeff Norenberg is Founder, CEO and Chairman of iSeek Biopharma, a clinical-stage pharmaceutical company developing LFA-1-targeted radiopharmaceuticals for diagnostic imaging and cancer therapy. A radiopharmaceutical scientist with over 35 years’ experience, he leads iSeek’s strategy, to connect scientific priorities with its product roadmap. His expertise spans target biology, radiochemistry, biodistribution, dosimetry and first-in-human translation. He has held leadership roles at Clarity Pharmaceuticals and Invicro and is Emeritus Professor at the University of New Mexico. He holds 11 patents, has authored over 100 publications and delivered over 150 invited presentations. His research was supported by over $63 million in funding.
Format Preference

Seminars

Wednesday 24th February 2027
Targeting Immune Biology Beyond the Tumor Cell: Unlocking LFA-1 for Radiopharmaceutical Development
9:30 am
  • Explore LFA-1 on leukocytes as an emerging target to move beyond conventional tumor-cell receptor expression
  • Harness innate immune biology and leukocyte activity within the tumor environment to identify new opportunities for targeted imaging and therapy
  • Translate LFA-1-targeted ligands from imaging into therapeutic applications, leveraging early clinical validation to inform next-generation development

Novel Target

Jeff Norenberg, Speaker at 3rd TRP Target Selection & Drug Design Summit